Modality
ADC
MOA
TNFi
Target
VEGF
Pathway
Tau
ALSCervical Ca
Development Pipeline
Preclinical
~Dec 2017
→ ~Mar 2019
Phase 1
~Jun 2019
→ ~Sep 2020
Phase 2
~Dec 2020
→ ~Mar 2022
Phase 3
~Jun 2022
→ ~Sep 2023
NDA/BLA
~Dec 2023
→ ~Mar 2025
Approved
Jun 2025
→ Jan 2031
ApprovedCurrent
NCT08876940
83 pts·ALS
2025-06→2031-01·Completed
83 total pts1 indication
CompletedCurrentUpcoming
Catalysts (1)
2031-01-104.8y awayPh3 Readout· ALS
Trial Timeline
Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031
Approved
Complet…
Catalysts
Ph3 Readout
2031-01-10 · 4.8y away
ALS
Completed|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT08876940 | Approved | ALS | Completed | 83 | ACR20 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Zanuderotide | Novartis | Phase 1/2 | VEGF | |
| AZN-7403 | AstraZeneca | Phase 2/3 | FGFR | |
| TAK-8730 | Takeda | Phase 2 | VEGF | |
| TAK-8262 | Takeda | NDA/BLA | Tau | |
| Talalemzoparlimab | Gilead Sciences | Phase 1 | FcRn | |
| GIL-2011 | Gilead Sciences | Preclinical | VEGF | |
| Bemazumab | Regeneron | Phase 1 | VEGF | |
| Ribozanubrutinib | Genmab | Approved | GPRC5D | |
| Pemicapivasertib | Legend Biotech | Phase 3 | VEGF | |
| Sematapinarof | Legend Biotech | NDA/BLA | VEGF |